ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
减肥药
1,234.31
-18.5131
-1.48%
涨家数:
2
跌家数:
5
平家数:
- -
市盈率:
- -
高:
1,252.86
开:
1,252.86
低:
1,211.75
收:
1,252.82
成交量:
6,754.35万
成交额:
56.91亿
市值:
1.31万亿
流通市值:
1.24万亿
数据加载中...
总览
新闻
特朗普:将大幅降价!巨头股价暴跌
央视财经
·
2小时前
诺和诺德:口服版Wegovy预计年底获批
DoNews
·
14小时前
礼来Verzenio®(Abemaciclib)在HR+、HER2-高风险早期乳腺癌患者中经过两年治疗延长生存期
美股速递
·
昨天
司美格鲁肽即将大降60%?相关谈判仍在进行中
健识局
·
昨天
赛诺菲启动10亿欧元胰岛素项目!百奥赛图IPO生效、IVD企业人事调整
医药经济报
·
昨天
诺和诺德终止细胞治疗、裁员约250人!
蒲公英Ouryao
·
昨天
诺和诺德欧股初段跌逾5% 公司减肥药被特朗普点名大幅降价
AASTOCKS
·
昨天
礼来股票在法兰克福下跌4.4%;特朗普表示竞争对手诺和诺德的减肥药价格将降低
美股速递
·
昨天
诺和诺德欧股开盘跌4.4%
每日经济新闻
·
昨天
诺和诺德欧股跌5%
格隆汇
·
昨天
推动跨境医药供应链标准化!诺和诺德在浦东的“智慧药仓”全面投入运营
外高桥之窗
·
昨天
诺和诺德引进MASP-3抗体;1.25亿元首付款,加科思转让子公司股权
氨基观察
·
昨天
近100亿美元!两大药企重磅收购
生物制品圈
·
昨天
GLP-1赛道火热,礼来竞争版图再添重要筹码!
制药网
·
昨天
医保基金即时结算改革;礼来口服GLP-1RA药物披露最新数据
21世纪经济报道
·
昨天
Viiv Healthcare: NICE对公司Cabotegravir进行积极推荐以供预防性使用
美股速递
·
昨天
Viiv Healthcare:在没有上诉的情况下,英国国家医疗服务体系应在威尔士两个月内、英格兰三个月内提供长期效应的Cabotegravir用于预防
美股速递
·
昨天
特朗普:Ozempic的成本可能为150美元。奥兹博士:尚未确定。
投资观察
·
昨天
BUZZ-C4 Therapeutics 溢价发行 1.25 亿美元股票后大涨
路透中文
·
昨天
安进涨0.90% 股价突破300美元大关
市场透视
·
10/16
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK4599/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"减肥药","latestPrice":1234.3102,"timestamp":1760731199999,"preClose":1252.8232,"halted":0,"volume":67543495,"delay":0,"changeRate":-0.014777,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-18.513062,"latestTime":"10-17 16:00:00 EDT","open":1252.8569,"high":1252.8569,"low":1211.7455,"amount":5690979166.784122,"amplitude":0.032815,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.963954,"peRate":26.541538,"turnoverRate":0.006384,"increases":2,"decrements":5,"flats":0,"marketCap":1307101867200,"floatMarketCap":1236793038560},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1252.8569,"amplitude":0.032815,"preClose":1252.8232,"low":1211.7455,"pbRate":"8.963954","latestPrice":1234.3102,"volume":67543495,"delay":0,"open":1252.8569,"prevYearClose":1305.0607,"prevWeekClose":1268.941,"prevMonthClose":1197.2607,"prevQuarterClose":1197.2607,"fiveDayClose":1268.941,"twentyDayClose":1201.3475,"sixtyDayClose":1297.9209,"secType":"PLATE","market":"US","turnoverRate":0.006384,"peRate":26.541538,"marketCap":1307101867200,"floatMarketCap":1236793038560,"timestamp":1760731199999,"nameCN":"减肥药"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":2,"down":5,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576011679","title":"特朗普:将大幅降价!巨头股价暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2576011679","media":"央视财经","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576011679?lang=zh_cn&edition=fundamental","pubTime":"2025-10-18 19:09","pubTimestamp":1760785752,"startTime":"0","endTime":"0","summary":"美国总统特朗普16日表示,包括丹麦诺和诺德公司生产的药物诺和泰在内,热门糖尿病及减重药物在美国的售价将大幅下降,这引发了市场医药板块震荡。17日,诺和诺德在哥本哈根交易的股票价格出现大跌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510183537913044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4532","BK4585","LU0154236417.USD","01477","BK4007","BK4599","IE00BKVL7J92.USD","NVO","LU1093756168.USD","LU1093756325.SGD","BK1574","IE00BZ1G4Q59.USD","BK1191"],"gpt_icon":1},{"id":"2576060190","title":"诺和诺德:口服版Wegovy预计年底获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2576060190","media":"DoNews","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576060190?lang=zh_cn&edition=fundamental","pubTime":"2025-10-18 06:53","pubTimestamp":1760741583,"startTime":"0","endTime":"0","summary":"2025年10月18日,诺和诺德宣布已提交司美格鲁肽口服制剂(Wegovy)的上市申请,预计将在今年晚些时候获得批准。该制剂用于长期体重管理,若如期获批,将为患者提供更便捷的用药选择。此举被视为诺和诺德在肥胖症治疗领域的重要布局,有望进一步扩大其全球市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510180655099734a2cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510180655099734a2cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4585","IE00BZ1G4Q59.USD","NVO","LU1093756168.USD","BK4588","IE00BKVL7J92.USD","BK4532","BK4599","LU1093756325.SGD","BK4007"],"gpt_icon":0},{"id":"1159591341","title":"礼来Verzenio®(Abemaciclib)在HR+、HER2-高风险早期乳腺癌患者中经过两年治疗延长生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1159591341","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159591341?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 20:04","pubTimestamp":1760702668,"startTime":"0","endTime":"0","summary":"礼来Verzenio®(Abemaciclib)在HR+、HER2-高风险早期乳腺癌患者中经过两年治疗延长生存期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4533","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0203202063.USD","LU0320765059.SGD","LU2360106947.USD","LU1623119135.USD","LU1712237335.SGD","LU2471134796.USD","IE00BK4W5M84.HKD","LU1868837300.USD","LU1917777945.USD","BK4581","SG9999018857.SGD","LU0823434740.USD","LU1720051108.HKD","LU0266013472.USD","LU0353189763.USD","LU0109391861.USD","LU2746668974.SGD","LU2112291526.USD","IE00B2B36J28.USD","BK4516","LU1061106388.HKD","SG9999015978.USD","LU2237443895.HKD","LU0061475181.USD","LU0882574139.USD","LU2468319806.SGD","SG9999001176.SGD","LU0256863902.USD","LU2491050154.USD","LU0823434583.USD","LU2264538146.SGD","LU2746668461.USD","LU1551013342.USD","LU0882574055.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU1804176565.USD","LLY","LU0640476718.USD","LU0058720904.USD","LU0354030511.USD","LU0466842654.USD","LU1868837136.USD","LU1720051017.SGD","LU2471134879.HKD","LU0006306889.USD","LU2361044865.SGD","IE00BK4W5L77.USD","LU1988902786.USD","LU2237443622.USD","LU2456880835.USD","LU2491050071.SGD","LU0198837287.USD","LU0094547139.USD","LU1989771016.USD","SGXZ99366536.SGD","LU0943347566.SGD","LU1974910355.USD","LU0114720955.EUR","IE0004445239.USD","LU1057294990.SGD","LU2237443978.SGD","LU0786609619.USD","IE00BFTCPJ56.SGD","LU0203201768.USD","LU1983299246.USD","LU0316494557.USD","LU1868836591.USD","SG9999014880.SGD","SG9999015986.USD","LU1291159041.SGD","LU0417517546.SGD","LU1267930730.SGD","SG9999014914.USD","LU2361044949.HKD","LU0820561818.USD","LU1232071149.USD","LU2108987350.USD","LU0889565916.HKD","BK4534","LU2265009873.SGD","LU1366192091.USD","LU2552382132.HKD","SGXZ51526630.SGD","BK4588","BK4599","LU0689472784.USD","LU2602419157.SGD","LU0471298777.SGD","SG9999013999.USD","SG9999015945.SGD","LU0353189680.USD","IE00BJLML261.HKD","LU0238689110.USD","LU2357305700.SGD","SG9999017495.SGD","LU1093756168.USD","LU0079474960.USD","LU2237443382.USD","LU2552382215.SGD","IE0002141913.USD","LU1069344957.HKD","BK4007","LU2461242641.AUD","LU0708995401.HKD","LU2106854487.HKD","LU1127390331.HKD","SG9999015952.SGD","LU2750360997.AUD","LU1868836914.USD","LU2361045086.USD","LU0354030438.USD","LU2750360641.GBP","LU2089984988.USD","LU2063271972.USD","BK4585","LU2211815571.USD","LU1814569148.SGD","LU1868836757.USD","LU2471134523.USD","SGXZ81514606.USD","LU0471298694.HKD","IE0009355771.USD","LU2237443465.HKD","LU0456855351.SGD","LU0097036916.USD","LU1064131342.USD","LU2023250504.SGD","LU0823416689.USD","LU0096364046.USD","LU2237438978.USD","GB00BDT5M118.USD","LU0432979614.USD","SG9999018865.SGD","LU0385154629.USD","SG9999014906.USD","LU1548497426.USD","LU2462157665.USD","LU0320765992.SGD","LU2471134952.CNY","LU1023059063.AUD","LU0234572021.USD","LU2324357040.USD","SGXZ31699556.SGD","LU0122379950.USD","LU2417539215.USD","LU2087625088.SGD","LU0106261372.USD","SG9999001176.USD","LU2237443549.SGD","LU2491049909.HKD","LU0672654240.SGD","LU0289739699.SGD","LU2236285917.USD","LU0323591593.USD","LU1280957306.USD","LU1551013425.SGD","LU2552382058.USD","SG9999014898.SGD","LU1035775433.USD","LU0256863811.USD","LU0820561909.HKD","IE00B1BXHZ80.USD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2576192060","title":"司美格鲁肽即将大降60%?相关谈判仍在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2576192060","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576192060?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 19:57","pubTimestamp":1760702231,"startTime":"0","endTime":"0","summary":"10月16日,国外媒体报道称:美国总统特朗普称热门降糖药物司美格鲁肽在美国的价格可能降至每月仅150美元,比此前每月499美元价格降幅高达60%。根据美国白宫椭圆形办公室的新闻发布会的消息,司美格鲁肽的自付费用将降至150美元。当广大糖尿病患者登陆这个平台支付购买司美格鲁肽,价格为每个月499美元,相较于之前的价格降低50%。美国要求跨国药企将基础治疗药物大幅降价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017200706a6bed836&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017200706a6bed836&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0868494617.USD","LU0122379950.USD","LU0170899867.USD","IE00B19Z3B42.SGD","LU0225771236.USD","IE00BBT3K403.USD","LU1057294990.SGD","SG9999002232.USD","SG9999011175.SGD","SG9999002224.SGD","SG9999013999.USD","IE00BZ1G4Q59.USD","BK4581","BK4532","LU1894683264.USD","SG9999003800.SGD","LU1023059063.AUD","LU1894683348.USD","BK4534","LU0225284248.USD","BK4588","LU1066053197.SGD","BK4592","LU0985481810.HKD","LU0306806265.USD","LU0321505868.SGD","LU0289739699.SGD","SG9999001176.USD","BK4585","IE000M9KFDE8.USD","LU0058720904.USD","LU0234572021.USD","IE00BLSP4239.USD","BK4550","NVO","IE00BLSP4452.SGD","BK4007","LU0154236417.USD","LU1883839398.USD","IE0002270589.USD","LU0321505439.SGD","LU0306807586.USD","BK4533","BK4599","LU0456855351.SGD","SG9999001176.SGD","IE00B19Z3581.USD","BK4568","LU1093756168.USD"],"gpt_icon":1},{"id":"2576060124","title":"赛诺菲启动10亿欧元胰岛素项目!百奥赛图IPO生效、IVD企业人事调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2576060124","media":"医药经济报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576060124?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 19:25","pubTimestamp":1760700302,"startTime":"0","endTime":"0","summary":"110亿欧元,赛诺菲北京胰岛素项目启动赛诺菲10月17日宣布,其位于北京经济技术开发区的胰岛素原料药项目正式启动。2百奥赛图科创板IPO注册生效10月16日,百奥赛图迎来了重大利好消息——中国证券监督管理委员会正式批复同意其首次公开发行股票并在科创板上市的注册申请。三位监事原定任期为2024年11月22日至2027年11月21日,本次监事职务免除后,王艳女士、杨洁女士和于美玲女士仍在公司工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017214202a4653c63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017214202a4653c63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4585","BK4599","IE00BZ1G4Q59.USD","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","BK4588","BK4007","LU1093756168.USD"],"gpt_icon":1},{"id":"2576060123","title":"诺和诺德终止细胞治疗、裁员约250人!","url":"https://stock-news.laohu8.com/highlight/detail?id=2576060123","media":"蒲公英Ouryao","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576060123?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 18:32","pubTimestamp":1760697137,"startTime":"0","endTime":"0","summary":"诺和诺德并非近期唯一退出细胞治疗领域的制药企业。近期武田制药也宣布终止其细胞治疗领域的研发工作。计划全球范围裁员9000人2025年09月,诺和诺德计划在其全球78400个岗位中裁员约9000人,裁员比例达11%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017195111a46515a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017195111a46515a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4588","BK4585","NVO","BK4007","IE00BKVL7J92.USD","BK4532","BK4599","LU1093756325.SGD","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2576084961","title":"诺和诺德欧股初段跌逾5% 公司减肥药被特朗普点名大幅降价","url":"https://stock-news.laohu8.com/highlight/detail?id=2576084961","media":"AASTOCKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576084961?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 16:00","pubTimestamp":1760688000,"startTime":"0","endTime":"0","summary":"丹麦诺和诺德药厂(Novo Nordisk)股价在欧洲早市跌5.6%,美国总统特朗普隔晚(16日)在一场关于生育治疗与药价的活动,点名该公司减肥药Ozempic将大幅降低售价。诺和诺德Ozempic药物获准用于治疗糖尿病,但与该集团畅销减肥药Wegovy含相同活性成分。Ozempic在美国经常被标签为用于肥胖治疗,并常...","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211229100131212_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211229100131212_s.jpg"],"rights":{"source":"aastocks_forex","url":"https://www.aastocks.com/sc/forex/news/comment.aspx?source=AAFN&id=NOW.1477393&catg=1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.aastocks.com/sc/forex/news/comment.aspx?source=AAFN&id=NOW.1477393&catg=1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_forex","symbols":["LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","BK4532","BK4588","BK4585","BK4007","LU0154236417.USD","BK4599","IE00BKVL7J92.USD","LU1093756325.SGD"],"gpt_icon":0},{"id":"1168962212","title":"礼来股票在法兰克福下跌4.4%;特朗普表示竞争对手诺和诺德的减肥药价格将降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1168962212","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168962212?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 15:37","pubTimestamp":1760686633,"startTime":"0","endTime":"0","summary":"礼来股票在法兰克福下跌了4.4%;特朗普表示竞争对手诺和诺德的减肥药价格将会降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203202063.USD","SG9999015952.SGD","LU2063271972.USD","LU0471298694.HKD","SGXZ51526630.SGD","LU0256863902.USD","LU2361045086.USD","LU1974910355.USD","LU0353189763.USD","LU1868837300.USD","LU0234572021.USD","LU2468319806.SGD","LU1023059063.AUD","LU0708995401.HKD","LU2108987350.USD","LU0114720955.EUR","LU1035775433.USD","LU2112291526.USD","LU1267930730.SGD","IE0002141913.USD","LU0094547139.USD","IE0009355771.USD","LU0823416689.USD","LU1989771016.USD","SG9999015945.SGD","BK4516","LU2237443895.HKD","LU2750360997.AUD","LU0640476718.USD","LU1917777945.USD","LU0106261372.USD","LU0109391861.USD","LU1093756325.SGD","LU0203201768.USD","LU0385154629.USD","LU2417539215.USD","LU0316494557.USD","LU2357305700.SGD","LU2324357040.USD","LU2461242641.AUD","LU0006306889.USD","IE00BJT1NW94.SGD","LU1720051017.SGD","SG9999015986.USD","IE00BJLML261.HKD","LU2089984988.USD","LU2471134952.CNY","LU0354030511.USD","LU1814569148.SGD","LU2265009873.SGD","LU2237443465.HKD","LU0266013472.USD","LU0122379950.USD","LU0096364046.USD","LU0432979614.USD","LU1868836757.USD","SG9999015978.USD","LU0058720904.USD","LU2746668461.USD","BK4585","LU0943347566.SGD","IE00BK4W5M84.HKD","SG9999017495.SGD","LU0786609619.USD","LU0882574139.USD","LU2552382215.SGD","SG9999018857.SGD","LU2264538146.SGD","LU1988902786.USD","LU2746668974.SGD","SGXZ81514606.USD","LU2237443549.SGD","LU2360106947.USD","LU2750360641.GBP","LU2237438978.USD","SG9999014880.SGD","SG9999001176.USD","LU2471134879.HKD","LU1623119135.USD","LU1983299246.USD","SG9999014906.USD","LU0354030438.USD","SGXZ57979304.SGD","IE00B4R5TH58.HKD","LU2211815571.USD","LU2237443622.USD","LU1232071149.USD","LU0466842654.USD","SGXZ31699556.SGD","LU2552382132.HKD","LU2471134523.USD","BK4581","LU2106854487.HKD","LU1127390331.HKD","LU2361044865.SGD","LU1057294990.SGD","LU0323591593.USD","LU0353189680.USD","LU0456855351.SGD","LU1551013342.USD","SG9999014914.USD","LU1551013425.SGD","LU0238689110.USD","IE00B1BXHZ80.USD","SG9999013999.USD","LU1093756168.USD","LU2456880835.USD","LU2602419157.SGD","LLY","LU2552382058.USD","LU2087625088.SGD","BK4534","LU0823434740.USD","LU0320765059.SGD","LU2491049909.HKD","SGXZ99366536.SGD","LU0061475181.USD","LU1868837136.USD","LU0820561818.USD","LU0820561909.HKD","LU1280957306.USD","SG9999001176.SGD","LU0689472784.USD","IE00BFTCPJ56.SGD","SG9999018865.SGD","LU0471298777.SGD","LU1061106388.HKD","LU2237443382.USD","BK4007","LU0079474960.USD","LU0320765992.SGD","LU1712237335.SGD","LU1064131342.USD","LU0198837287.USD","LU1069344957.HKD","LU2361044949.HKD","LU2023250504.SGD","LU0889565916.HKD","LU0097036916.USD","LU1366192091.USD","LU0417517546.SGD","LU0109394709.USD","LU0882574055.USD","LU1548497426.USD","BK4599","BK4533","LU1720051108.HKD","LU2462157665.USD","LU2236285917.USD","LU2237443978.SGD","IE00BK4W5L77.USD","LU1868836591.USD","IE0004445239.USD","LU2491050071.SGD","IE00B2B36J28.USD","LU2491050154.USD","IE00BJJMRZ35.SGD","GB00BDT5M118.USD","LU0672654240.SGD","LU0289739699.SGD","LU1868836914.USD","LU1291159041.SGD","LU0823434583.USD","LU1804176565.USD","LU2471134796.USD","SG9999014898.SGD","BK4588","LU0256863811.USD"],"gpt_icon":0},{"id":"2576954089","title":"诺和诺德欧股开盘跌4.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576954089","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576954089?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 15:13","pubTimestamp":1760685223,"startTime":"0","endTime":"0","summary":"诺和诺德欧股开盘跌4.4%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510173537228237.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173537228237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0154236417.USD","BK4532","IE00BKVL7J92.USD","BK4007","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVO","LU1093756168.USD","BK4588","BK4599","BK4585"],"gpt_icon":0},{"id":"2576086420","title":"诺和诺德欧股跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576086420","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576086420?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 15:12","pubTimestamp":1760685134,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","NVO","LU1093756168.USD","BK4588","BK4007","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4532","IE00BKVL7J92.USD","LU1093756325.SGD","BK4599"],"gpt_icon":0},{"id":"2576060117","title":"推动跨境医药供应链标准化!诺和诺德在浦东的“智慧药仓”全面投入运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2576060117","media":"外高桥之窗","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576060117?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 12:15","pubTimestamp":1760674558,"startTime":"0","endTime":"0","summary":"今年5月,诺和诺德中国开放创新中心获得浦东新区政府正式授牌,加入浦东“大企业开放创新中心”计划。诺和诺德全球高级副总裁兼大中国区总裁周霞萍表示,“位于上海的仓储和物流中心是我们在华供应链的关键一环,强化了上海在诺和诺德中国布局中的商业运营和创新引擎地位。我们将继续履行对患者的长期承诺,共同推动跨境医药供应链的标准化和现代化,同时,也将继续助力上海加快打造世界级生物医药产业集群。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017122318a6be2b7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017122318a6be2b7f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4588","BK4532","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","BK4599","IE00BKVL7J92.USD","LU0154236417.USD","BK4007","BK4585"],"gpt_icon":1},{"id":"2576118060","title":"诺和诺德引进MASP-3抗体;1.25亿元首付款,加科思转让子公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2576118060","media":"氨基观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576118060?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 10:39","pubTimestamp":1760668791,"startTime":"0","endTime":"0","summary":"10月15日,诺和诺德宣布,引进Omeros的MASP-3抗体OMS906,用于治疗罕见血液疾病和肾脏疾病。根据本次协议,海松资本将以人民币1.25亿元首付款及7500万元里程碑付款收购北京加科思旗下北京加科瑞康医药科技有限公司80%的股权。2)加科思转让子公司股权日前,加科思宣布,与海松资本及一名产业合作方签署增资及股权转让协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101710571894ce382c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101710571894ce382c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4588","LU1093756325.SGD","BK4532","NVO","LU1093756168.USD","BK4599","LU0154236417.USD","BK4007","IE00BKVL7J92.USD","BK4585"],"gpt_icon":1},{"id":"2576706019","title":"近100亿美元!两大药企重磅收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2576706019","media":"生物制品圈","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576706019?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 10:13","pubTimestamp":1760667185,"startTime":"0","endTime":"0","summary":"诺和诺德、BMS重磅收购,今年的并购浪潮高过以往。10月9日,诺和诺德与Akero Therapeutics达成收购协议,预付款为47亿美元,加上CVR合计52亿美元。10月10日,百时美施贵宝宣布将以15亿美元收购一家专注于体内CAR-T疗法的公司——Tevogen。两天时间,两家巨头,合计投入近100亿美元,药企并购热情持续高涨。据不完全统计,2025年以来,医药行业已发生超10起重大收购案,其中不乏总金额超百亿美元的案例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017114542a6be200d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017114542a6be200d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4230","LU1093756168.USD","BK4007","BK4599","BMS","NVO","LU1093756325.SGD","BK4588","BK4022","IE00BKVL7J92.USD","BK4585","LU0154236417.USD","IE00BZ1G4Q59.USD","CAR","BK4532"],"gpt_icon":1},{"id":"2576129060","title":"GLP-1赛道火热,礼来竞争版图再添重要筹码!","url":"https://stock-news.laohu8.com/highlight/detail?id=2576129060","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576129060?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 09:33","pubTimestamp":1760664813,"startTime":"0","endTime":"0","summary":"10月15日,礼来公布orforglipron两项3期临床试验顶线结果,为火热的GLP-1赛道投下了一枚关键砝码。从整个 GLP-1 赛道的发展趋势来看,orforglipron 的临床成功可能会进一步加速行业的技术迭代方向。此外,随着 GLP-1 药物市场规模的扩大,支付端的压力也可能逐渐显现,未来药物的定价策略、医保谈判进展等,也将成为影响市场竞争格局的重要因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510170938029732e396&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510170938029732e396&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2746668461.USD","BK4599","IE00B4R5TH58.HKD","LU0122379950.USD","SG9999014880.SGD","LU0820561818.USD","LU0820561909.HKD","LU2063271972.USD","LU2237438978.USD","LU0471298777.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU0106261372.USD","LU0353189763.USD","LU2265009873.SGD","LU0320765059.SGD","LU0198837287.USD","LU0708995401.HKD","BK4533","LU1291159041.SGD","LU0061475181.USD","LU2602419157.SGD","LU0456855351.SGD","BK4590","SGXZ51526630.SGD","IE00BJJMRZ35.SGD","LU0097036916.USD","LU0786609619.USD","LU0266013472.USD","LU2324357040.USD","LU0466842654.USD","LU2087625088.SGD","LU0417517546.SGD","LLY","LU1267930730.SGD","LU0385154629.USD","LU0316494557.USD","LU1548497426.USD","LU2360106947.USD","BK4585","SG9999018857.SGD","GLP","SGXZ57979304.SGD","LU0109394709.USD","BK4534","LU1093756168.USD","LU0256863811.USD","LU0203202063.USD"],"gpt_icon":1},{"id":"2576777621","title":"医保基金即时结算改革;礼来口服GLP-1RA药物披露最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2576777621","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576777621?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 08:03","pubTimestamp":1760659396,"startTime":"0","endTime":"0","summary":"政策动向国家医保局:2025年底前全国所有统筹地区均需开展即时结算10月16日,国家医疗保障局办公室发布关于全面推进医保基金即时结算改革扩面提质的通知,2025年底前全国所有统筹地区均需开展即时结算。各省级医保部门要重点指导未开展即时结算的统筹地区,加强组织协调,加大推进力度,确保如期完成目标任务。2026年底前实现即时结算资金占本地医保基金月结算资金的80%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510173536609797.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173536609797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE0009355771.USD","LU0256863811.USD","LU1291159041.SGD","LU2552382058.USD","IE00B4R5TH58.HKD","LLY","LU0097036916.USD","LU0238689110.USD","LU2552382132.HKD","LU0672654240.SGD","BK4599","LU1868836914.USD","LU0354030511.USD","LU2023250504.SGD","IE00BJJMRZ35.SGD","LU2265009873.SGD","LU0708995401.HKD","SG9999017495.SGD","LU2357305700.SGD","SG9999018865.SGD","LU2462157665.USD","LU1551013342.USD","LU2361044865.SGD","LU0889565916.HKD","GLP","LU0061475181.USD","LU1551013425.SGD","SG9999018857.SGD","SGXZ81514606.USD","LU0323591593.USD","LU0096364046.USD","LU2324357040.USD","LU0640476718.USD","LU2361044949.HKD","LU2552382215.SGD","BK4590","SG9999014906.USD","SG9999014914.USD","GB00BDT5M118.USD","LU0266013472.USD","LU1868836591.USD","LU2746668461.USD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU1366192091.USD","LU1917777945.USD","LU1868836757.USD","LU0354030438.USD","LU0256863902.USD","LU2360106947.USD"],"gpt_icon":1},{"id":"1146233885","title":"Viiv Healthcare: NICE对公司Cabotegravir进行积极推荐以供预防性使用","url":"https://stock-news.laohu8.com/highlight/detail?id=1146233885","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146233885?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 07:02","pubTimestamp":1760655740,"startTime":"0","endTime":"0","summary":"Viiv Healthcare: NICE对公司Cabotegravir进行积极推荐以供预防性使用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1098665638.USD","IE00BQJZX424.USD","BK4534","SG9999003800.SGD","LU0203345920.USD","LU0321505868.SGD","LU1645745479.HKD","SG9999001176.USD","LU0456855351.SGD","LU0234572021.USD","LU0289739699.SGD","LU1309081286.SGD","LU1064927863.SGD","LU1035777561.USD","LU0058720904.USD","LU1487256676.USD","BK4533","IE0002270589.USD","LU1670756490.USD","GSK.UK","LU1057294990.SGD","LU0109981661.USD","LU1400636491.USD","LU0868494617.USD","IE00BLSP4239.USD","SG9999013999.USD","LU0545562505.USD","SG9999002232.USD","LU1481600234.SGD","LU0203347892.USD","LU1894683264.USD","LU1400636657.SGD","LU0170899867.USD","LU0161305163.EUR","LU0985481810.HKD","LU1883839398.USD","BK4599","PFE","BK4007","LU0225284248.USD","IE00BWDBJ516.SGD","LU1066051498.USD","LU1302929846.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","LU1015430645.USD","BK4568","LU0321505439.SGD","IE00BLSP4452.SGD","LU1066053197.SGD","LU1046248800.SGD","LU0971552673.USD","LU1202635105.USD","BK5011","LU1894683348.USD","BK4581","LU0122379950.USD","LU1228905540.USD","LU1400636574.HKD","BK4592","SG9999011175.SGD","LU1228905037.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0971552830.HKD","LU0225771236.USD","SGXZ57979304.SGD","IE0034235071.USD","LU0306806265.USD","BK4585","IE000M9KFDE8.USD","BK4588","LU0575583348.USD","LU0306807586.USD","LU0211331839.USD","SG9999001176.SGD","SG9999002224.SGD","LU1481599808.USD","BK4550"],"gpt_icon":0},{"id":"1157772696","title":"Viiv Healthcare:在没有上诉的情况下,英国国家医疗服务体系应在威尔士两个月内、英格兰三个月内提供长期效应的Cabotegravir用于预防","url":"https://stock-news.laohu8.com/highlight/detail?id=1157772696","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157772696?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 07:02","pubTimestamp":1760655732,"startTime":"0","endTime":"0","summary":"Viiv Healthcare:在没有上诉的情况下,英国国家医疗服务体系应在威尔士两个月内、英格兰三个月内提供长期效应的Cabotegravir用于预防","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK4581","LU1481600234.SGD","IE00BLSP4239.USD","BK4599","LU0575583348.USD","LU1883839398.USD","SG9999002224.SGD","LU1309081286.SGD","SGXZ57979304.SGD","LU0122379950.USD","BK4585","IE000M9KFDE8.USD","LU0545562505.USD","LU1400636574.HKD","LU1481599808.USD","LU1057294990.SGD","LU1064927863.SGD","PFE","BK4592","IE00BWDBJ516.SGD","BK4534","BK4550","LU0203345920.USD","LU0321505439.SGD","SG9999001176.SGD","IE00BQJZX424.USD","LU1228905037.USD","BK4588","IE00BBT3K403.USD","SG9999002232.USD","LU1202635105.USD","LU1670756490.USD","IE0034235071.USD","LU0161305163.EUR","BK5011","LU0306807586.USD","LU1015430645.USD","LU1023059063.AUD","LU1400636491.USD","IE0002270589.USD","BK4533","BK4007","LU1894683348.USD","LU1302929846.USD","IE00BLSP4452.SGD","LU0868494617.USD","LU1487256676.USD","GSK.UK","SG9999013999.USD","LU0225771236.USD","LU0289739699.SGD","LU0321505868.SGD","LU0971552830.HKD","LU0058720904.USD","LU0203347892.USD","LU1228905540.USD","LU0170899867.USD","LU0985481810.HKD","LU0225284248.USD","LU1035777561.USD","SG9999001176.USD","LU1066053197.SGD","LU1400636657.SGD","LU0234572021.USD","LU1066051498.USD","LU1046248800.SGD","LU1894683264.USD","SG9999011175.SGD","LU0306806265.USD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU0211331839.USD","LU1098665638.USD","LU0109981661.USD","LU1645745479.HKD","LU0971552673.USD","BK4568","LU0456855351.SGD"],"gpt_icon":0},{"id":"1178563125","title":"特朗普:Ozempic的成本可能为150美元。奥兹博士:尚未确定。","url":"https://stock-news.laohu8.com/highlight/detail?id=1178563125","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178563125?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 05:10","pubTimestamp":1760649038,"startTime":"0","endTime":"0","summary":"特朗普总统于周四在白宫椭圆形办公室表示,Ozempic,即“减肥药”,的成本可能为150美元,或者“远低于”目前的价格。医疗保险与医疗补助服务中心的管理员梅梅特·奥兹博士插话说,这些药物的价格尚未谈判。政府正在与多家制药公司协商药品价格,并且已经与辉瑞(Pfizer)和阿斯利康(AstraZeneca)达成了协议。\n“但是它会的,”特朗普说。随后奥兹表示:“总统会对结果感到满意,在他满意之前,我们不会结束谈判。”诺和诺德(Novo Nordisk, NVO),即Ozempic的生产商,股票在纽约的盘后交易中下跌了约3.5%。\n(完)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","LU0234572021.USD","LU0154236417.USD","IE0002270589.USD","LU1066051498.USD","LU0456855351.SGD","IE00BLSP4239.USD","SG9999002232.USD","LU1023059063.AUD","LU1883839398.USD","BK4599","LU1057294990.SGD","LU0058720904.USD","BK4592","LU1093756168.USD","IE000M9KFDE8.USD","SG9999013999.USD","IE00BZ1G4Q59.USD","LU0306806265.USD","BK4581","IE00BKVL7J92.USD","NVO","LU0225284248.USD","LU0306807586.USD","BK4568","SG9999002224.SGD","LU0321505439.SGD","PFE","LU1894683348.USD","SG9999011175.SGD","BK4532","BK4550","LU0122379950.USD","LU0868494617.USD","BK4534","LU0170899867.USD","BK4533","LU0321505868.SGD","BK4585","LU0985481810.HKD","SGXZ57979304.SGD","LU0225771236.USD","SG9999001176.USD","IE00BBT3K403.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4588","LU0289739699.SGD","SG9999003800.SGD","LU1066053197.SGD","LU1093756325.SGD","LU1894683264.USD","IE00BLSP4452.SGD","BK4007"],"gpt_icon":0},{"id":"2576372455","title":"BUZZ-C4 Therapeutics 溢价发行 1.25 亿美元股票后大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2576372455","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576372455?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 01:59","pubTimestamp":1760637556,"startTime":"0","endTime":"0","summary":"** C4 Therapeutics CCCCC.O溢价融资后,该公司股价周四上涨25%至2.78美元。** 合并发行价为 2.47 美元,而该股在周三的最后成交价为 2.22 美元。** 随着本交易日的上涨,CCCC 累计下跌 23(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL3S3VX1D5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985481810.HKD","BK4585","SG9999002224.SGD","LU0456855351.SGD","BK4550","LU0868494617.USD","SG9999002232.USD","LU1066053197.SGD","LU0058720904.USD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU0306807586.USD","SG9999013999.USD","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU0321505868.SGD","LU1894683348.USD","SG9999003800.SGD","LU1066051498.USD","LU1894683264.USD","LU0289739699.SGD","SG9999001176.SGD","BK4588","SG9999001176.USD","BK4139","IE00B19Z3581.USD","BK4592","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0321505439.SGD","LU1057294990.SGD","BK4534","LU0225771236.USD","LU0306806265.USD","LU0170899867.USD","SGXZ57979304.SGD","LU0225284248.USD","EVR","SG9999011175.SGD","BK4581","CCCC","BK4127","LU1883839398.USD","BK4007","BK4568","BK4533","LU0234572021.USD","IE0002270589.USD","BK4599"],"gpt_icon":1},{"id":"2576570703","title":"安进涨0.90% 股价突破300美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2576570703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576570703?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 21:57","pubTimestamp":1760623026,"startTime":"0","endTime":"0","summary":"北京时间2025年10月16日21时57分,安进股票出现异动,股价急速拉升0.90%。截至发稿,该股报300.00美元/股,成交量11.2623万股,换手率0.02%,振幅0.81%。安进股票所在的制药行业中,整体涨幅为0.63%。安进于 2006 年推出了首款癌症治疗药物 Vectibix,并销售骨强化药物 Prolia/Xgeva和 Evenity。公司2023年收购Horizon带来了多种罕见疾病药物,包括甲状腺眼病药物Tepezza。同时,安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016215706a6bd2908&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016215706a6bd2908&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU0320765992.SGD","LU0058720904.USD","LU0289739699.SGD","LU2242652126.USD","LU0109394709.USD","BK4533","IE0002141913.USD","BK4581","LU0122379950.USD","LU2112291526.USD","IE00B4R5TH58.HKD","LU2089984988.USD","IE00BJT1NW94.SGD","BK4588","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK4599","LU2242646821.SGD","LU2468319806.SGD","BK4566","LU1061106388.HKD","IE0009355771.USD","SG9999001440.SGD","LU1983299246.USD","BK4534","LU1057294990.SGD","LU0868494617.USD","AMGN","BK4139","IE00B2B36J28.USD","LU0889565916.HKD","LU1571399168.USD","LU1023059063.AUD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":84,"code":"91000000","status":"200"}]}}